StreetAlpha.app
Home › Stocks › MDWD

MediWound Ltd. (MDWD)

Members
LATEST PRICE

MediWound develops enzyme-based therapies that remove damaged tissue from burns and chronic wounds. MDWD reports earnings on Thu, Nov 19, 2026.

Prices, price targets and earnings estimates for MDWD are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is MDWD in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 19
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated MDWD in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for MDWDThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
OppenheimerMaintained
Aug 14Buy
OppenheimerMaintained
May 28Buy
HC Wainwright & Co.Reiterated
May 28Buy
DateFirmActionRatingPrice target
Aug 14OppenheimerMaintainedBuy
May 28OppenheimerMaintainedBuy
May 28HC Wainwright & Co.ReiteratedBuy
Loading…

Whale Options Flow

90D

No whale options trades in MDWD in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MDWD is in one of them and how their past MDWD trades turned out.

See how it works→ View all auto pilots→
MDWD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MDWD in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About MediWound

MediWound develops enzyme-based therapies that remove damaged tissue from wounds while leaving healthy tissue in place. Its main product, NexoBrid, treats deep burns and is approved in many countries. The company is also developing EscharEx, a topical treatment for chronic wounds such as venous leg ulcers, and a candidate for basal cell carcinoma. It makes its products at its facility in Yavne, Israel, and its customers are hospitals and healthcare providers treating burn and wound patients.

Headquarters
Yavne, Israel
Summary based on the company’s 2026 annual report (20-F) ↗